Provided by Tiger Trade Technology Pte. Ltd.

GENSCRIPT BIO

33.880
-1.140-3.26%
Volume:50.83M
Turnover:1.71B
Market Cap:74.47B
PE:-17.58
High:35.180
Open:33.980
Low:32.960
Close:35.020
52wk High:36.100
52wk Low:10.360
Shares:2.20B
HK Float Shares:2.20B
Volume Ratio:1.39
T/O Rate:2.31%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.927
ROE:-15.33%
ROA:1.54%
PB:2.44
PE(LYR):-17.58
PS:11.24

Loading ...

Genscript Reports 27.3% First-Half 2026 Revenue Growth as AI Drug Discovery Business Doubles

THOMSON REUTERS
·
Aug 18

Global Food Inflation Risks Return While Robotics Stocks Rally on Yushu Tech's Upcoming Debut

Stock News
·
Aug 18

Hong Kong Stocks Decline 0.3% in Early Trading

Dow Jones
·
Aug 18

HK Movers | Pharma Stocks Rally With Genscript Biotech up 6%, WuXi Biologics up 5%

Tiger Newspress
·
Aug 18

Movement Alert|GENSCRIPT BIO Rises 7.82% in Regular Trading, Interim Results Significantly Beat Expectations with AIDD Business Doubling

Market Focus
·
Aug 18

Genscript Biotech (SEHK:1548) Stock Near Doubles As Losses Deepen

Simply Wall St.
·
Aug 17

Asian Market's Estimated Value Stocks For August 2026

Simply Wall St.
·
Aug 17

Hong Kong Stock Moves: GENSCRIPT BIO Surges Over 4% as AIDD-Related Business Doubles in First Half

Stock News
·
Aug 17

HK Movers | Pharma Stocks Gain With HUTCHMED up 8%, JOINN up 6%

Tiger Newspress
·
Aug 17

Movement Alert|GENSCRIPT BIO Rises 3.3% in Regular Trading, H1 Adjusted Net Profit Surges 203% as AIDD Demand Accelerates

Market Focus
·
Aug 17

Genscript Biotech Widens Net Loss in H1

MT Newswires Live
·
Aug 17

GENSCRIPT BIO 2026 Interim Results: Soaring AIDD Demand Unlocks Vast Market Opportunities, Revenue and Profit Growth Far Exceeds Expectations, Core Businesses Achieve Comprehensive Breakthrough

Deep News
·
Aug 16

GenScript Biotech Posts 27.3% Revenue Growth and 203.3% Surge in Adjusted Profit in H1 2026, While Equity Accounting Hit Drives US$129.34 Million Net Loss

Bulletin Express
·
Aug 16

Genscript Biotech Says H1 Adjusted Net Profit up 203.3% Y/Y, Revenue up 27.3%

THOMSON REUTERS
·
Aug 16

GENSCRIPT BIO Reports Interim Results: Net Loss Narrows 29.25% to $129 Million

Stock News
·
Aug 16

GenScript FY26 H1 Net Loss Narrows 28.9% to US$ 129.34 Million; Revenue Rises 27.3% to US$ 404.22 Million

Reuters
·
Aug 16

Movement Alert|GENSCRIPT BIO Falls 3.31% in Regular Trading, Trading at HK$25.12

Market Focus
·
Aug 14

Movement Alert|GENSCRIPT BIO Rises 3.7% in Regular Trading, AI Pharma Delivery and CARVYKTI Sales Surge Continue to Drive Momentum

Market Focus
·
Aug 13

Movement Alert|GENSCRIPT BIO Rises 3.1% in Regular Trading, AI Pharma Commercialization and CARVYKTI Sales Surge Continue to Drive Momentum

Market Focus
·
Aug 12

GenScript Biotech Announces Legend Biotech Form 6-K for Q2 Ended June 30, 2026

Reuters
·
Aug 11